Public Health Initiatives

Advancing Public Health Through Access and Evidence

Knoa Pharma is committed to addressing critical public health challenges related to opioid use disorder and opioid overdose.

Our Public Health Initiatives are evidence-based efforts focused on expanding access to lifesaving overdose reversal tools and medication for opioid use disorder. These initiatives operate under a not-for-profit model designed to make treatments available at or below the cost of production.

Areas of Focus

Expanding Access to Evidence-Based Treatment

Medications for opioid use disorder (MOUD) remain underutilized, particularly in correctional settings and during transitions back to the community.^1,2,3

Knoa Pharma’s public health efforts focus on reducing barriers to access and supporting continuity of care for populations at increased risk.

Enhancing Community Overdose Prevention and Response

The ongoing and evolving overdose crisis, driven largely by potent synthetic opioids,⁴ highlights the need for harm reduction strategies and multiple clinically appropriate treatment options.

Knoa Pharma supports initiatives that strengthen overdose preparedness and response across emergency, prehospital, and healthcare settings.

Deepening Learning and Collaboration to Address the Evolving Opioid Crisis

Real-world data and outcomes research are essential to understanding the evolving opioid crisis, how overdose interventions and treatments for opioid use disorder are used in practice, and how they influence patient outcomes, healthcare resource utilization, and transitions to ongoing care.

To advance this work, Knoa Pharma invests in research partnerships and observational studies designed to address critical evidence gaps related to opioid overdose treatment. These efforts support responsible, data-driven public health decision-making and align with expert recommendations for continued evidence development.

References: